32 results about "Basophilia" patented technology

A hybrid protein contains a protein that binds to a receptor of mastocytes and basophils and is endocyted by them. The protein can be IgE; IgE fragment; IgE Fc fragment; antibody against IgE receptor of mastocytes and basophils; fragment of the antibody against the IgE receptor of mastocytes and basophils; antibody against mastocyte specific potassium channel; and mast cell degranulating peptide. The hybrid protein also contains a protease cleaving proteins of the secretion process of the mastocytes and basophils so as to inhibit the secretion process without killing the mastocytes and basophils. The protease can be light chain Clostridium botulinum toxin; proteolytically active fragment of the light chain of a Clostridium botulinum toxin containing an amino acid sequence His-Xaa-Xaa-Xaa-His-Xaa-Xaa-His wherein Xaa is an amino acid; light chain of the tetanus toxin; proteolytically active fragment of the light chain of the tetanus toxin containing His-Asp-Leu-lIe-His-Val-Leu-His; IgA protease of Neisseria gonorrhoeae; and proteolytic domain of the IgA protease of Neisseria gonorrhoeae.

Non-allergic hypersensitivity reactions can be observed in a sample of cells from a subject in response to anaphylatoxins. Accordingly, methods are provided for detecting clinical conditions such as cellular hyper-reactivity, non-allergic hypersensitivity, asthma, inflammation, chronic or acute infection, bacterial infection, viral infection, parasite infection, adverse drug reaction, organ rejection, vasculitis, mastocytosis, eosinophilia, basophilia, leukemia, and / or C3a or C5a receptor defects in a subject. Also provided are kits for detecting such clinical conditions in a subject.

Provided herein are systems and methods for analyzing blood samples, and more specifically for performing a basophil analysis. In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; and then (b) using measurements of light scatter and fluorescence emission to distinguish basophils from other WBC sub-populations. In one embodiment, the systems and methods include performing a basophil cluster analysis of the blood sample, based on the combination of light scatter and fluorescence measurements.

The present invention is based on the discovery that contrary to prior studies CD16 is expressed by basophils and as such provide methods and kits for enriching basophils in a blood sample.

The present invention relates to a method for identifying allergenic proteins and peptides. More specifically, the present invention provides a method for identifying allergenic milk proteins and / or peptides comprising the steps of: providing at least one expression library comprising DNA or cDNA derived from the mammary gland tissue of a lactating mammal, preferably a lactating cow, expressing at least one protein or peptide encoded by said expression library, determining the binding capacity of said at least one protein or peptide to IgE of at least one serum of an individual who is sensitive to mammalian milk,preferably cow's milk, contacting the at least one protein or peptide exhibiting an IgE binding with basophil cells, eosinophil cells or mast cells and identifying the at least one protein or peptide as being allergenic when said basophil cells, eosinophil cells or mast cells release upon contact with at least one protein or peptide at least one mediator.

The present invention relates to methods and kits for detecting basophil cells activation. The inventors showed that fluorescent avidin binds to basophil cell surface upon degranulation and that this probe can be used to monitor basophil degranulation More specifically the present invention relates to methods for monitoring of basophil degranulation using avidin-based probes. The method of the invention described here allows to measure direct basophil degranulation following FcεRI crosslinking with allergen. This method provides a direct measurement of degranulation by staining exteriorized granules and unambiguously detects activated basophils degranulated. The extent of the degranulation can be directly deduced from the intensity of fluorescence of fluorochrome-labelled avidin measured on basophils. When applied to allergic patient samples the avidin-based method detected efficiently specific basophil responses.

The invention belongs to the field of research and development of drugs and health-care products, and particularly relates to an application of nicotinamide mononucleotide and / or nicotinamide mononucleotide salt. The invention provides an application of the nicotinamide mononucleotide or the nicotinamide mononucleotide salt to anti-anaphylaxis drugs and / or anti-anaphylaxis health-care products. According to the technical scheme provided by the invention, after the nicotinamide mononucleotide or the nicotinamide mononucleotide salt (NMN) is used, Treg cells can be induced to secrete immunosuppression cytokine IL10, TGF-beta and the like, so that the immune reaction of TH2, blood basophilia and tissue mast cells can be restrained, sIgE synthesis is reduced, and finally the anaphylaxis symptoms can be alleviated; and further, through experimental determination, after the NMN is used, fewer adverse reactions exist, and the anaphylaxis recurrence rate is reduced. According to the application of the nicotinamide mononucleotide and / or the nicotinamide mononucleotide salt provided by the invention, the technical defects in the prior art that anti-anaphylaxis drugs have some adverse reactions, medication needs to be repeatedly performed, and the anaphylaxis recurs easily can be overcome.

The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and / or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.

The application discloses a sample analyzer and its counting method. The sample analyzer includes a control module, a first detection module and a second detection module. The control module is respectively connected to the first detection module and the second detection module. The counting method includes: The control module generates a first histogram based on the first measurement data of the first detection module; the control module obtains an area ratio based on the ratio of the first area to the total area of ​​the first histogram; the control module calculates the number of discrete particles in the second The number ratio of white blood cells in the detection module; the control module obtains the positive probability value of the sample based on multiple area ratios and number ratios; the control module obtains the proportion of basophils in white blood cells based on the positive probability value. Through the above method, the positive misjudgment rate of the sample can be reduced, the positive detection rate of the sample can be increased, and the reliability of the count value of basophils can be improved.

A method for identifying allergenic proteins and peptides. More specifically, a method for identifying allergenic milk proteins and / or peptides including the steps of: providing at least one expression library comprising DNA or cDNA derived from the mammary gland tissue of a lactating cow, expressing at least one protein or peptide encoded by said expression library, determining the binding capacity of said at least one protein or peptide to IgE of at least one serum of an individual who is sensitive to cow's milk, contacting the at least one protein or peptide exhibiting an IgE binding capacity as determined in step c) with basophil cells, eosinophil cells or mast cells and identifying the at least one protein or peptide as being allergenic when said basophil cells, eosinophil cells or mast cells release upon contact with at least one protein or peptide of step d) at least one mediator.

The invention discloses a method for preparing exosomes released by activated basophils, comprising the steps of: preparing basophils from anticoagulated peripheral blood of normal people by negative selection, passing Anti-IgE To stimulate activation, use serum-free culture at 37°C with 5% CO 2 Cultivate in an incubator for 12 to 48 hours, then collect the supernatant of the cell culture solution, centrifuge at room temperature at 300g, collect the supernatant of the culture solution after centrifugation, and obtain it by ultracentrifugation; the invention also discloses the full transcription of the above-mentioned exosomes Group expression profiles and methods for their construction. The present invention successfully isolated and identified the exosomes released by human basophils for the first time, and established the whole transcriptome expression profile of exosomes released by human basophils for the first time, and identified multiple post-activation differences The expressed RNA provides a new target for further research on the molecular mechanism of the interaction between activated basophils and target cells in the occurrence of diseases.

The invention provides a basophilic granulocyte activation and degranulation identification method. The basophilic granulocyte activation and degranulation identification method comprises the following steps that test samples are numbered in sequence, and flow type sample feeding pipes required by testing are marked; a required anti-human CD123, anti-human CCR3, anti-human HLA-DR, anti-human CD203c and / or anti-human CD63 fluorescence labeling flow type antibody combination is added into each flow type sample feeding pipe; mixed whole blood is added into the marked flow type pipes, and shading incubation is conducted at the indoor temperature; red blood cell lysate is added into each sample pipe, and shading incubation is conducted at the indoor temperature again; supernatant is removed in a centrifugal mode after incubation; detection is conducted by means of a flow cytometry, and the number of basophilic granulocytes and the average fluorescence intensity are analyzed. According to the basophilic granulocyte activation and degranulation identification method, 80%-100% of the basophilic granulocytes in peripheral blood can be distinguished from other types of cells under the condition that the basophilic granulocytes do not need to be separated or purified, the basophilic granulocyte activation and / or degranulation state can be identified, whole blood of no more than 100 microlitres is needed by each sample to be tested, and the repeatability is good.

According to an aspect of the present invention, there is provided an anti-I-type allergy agent including: p-coumaric acid as an active ingredient. In addition, according to another aspect of the present invention, there is provided an anti-dementia agent including: p-coumaric acid as an active ingredient.

The present invention belongs to the field of papermaking and discloses pectobacterium carotovorum and applications thereof in bio-pulping. The pectobacterium carotovorum subsp. carotovorum C519 is preserved in China General Microbiological Culture Collection Center with a preservation number is CGMCC No. 3350. The strain can grow under the condition of high alkalinity (pH 11), is suitable for degumming process of plant bast fibers and can be used for biological paper pulp. The C519 (CGMCC No. 3350) can grow under an alkaline condition (pH 9 to pH 11), and secretes basophilia pectin with high activities (an appropriate pH value is between 8 and 10). Other general microorganisms are difficult to grow and breed in the range of alkalinity, so that the strain can avoid being polluted by other competitors. Moreover, cellulose has no activities under the alkaline condition, thus the strain greatly keeps the original performance of the bast fibers and improves yield.

The present invention relates to a pharmaceutical composition, food composition and cosmetic composition for preventing, treating, or improving allergic diseases comprising extract or fraction of a plant of the Justicia genus as an active ingredient. The extract or a fraction of a plant of the Justicia genus according to the present invention can inhibit IgE antibody secretion and the degranulation of mast cells and basophils, and exhibits an excellent anti-allergic effect, and thus can effectively prevent, treat, or improve allergic diseases.

The invention discloses a basophilia mimic enzyme as well as a preparation method and application thereof. The preparation method comprises the following steps: pre-mixing a melamine aqueous solutionand a palladium salt aqueous solution, enabling melamine molecules to be combined with palladium ions by virtue of an electrostatic acting force, adding a reducing agent, stirring, and generating basophilia melamine protective nanopalladium, thus obtaining the basophilia mimic enzyme. The preparation method disclosed by the invention is simple in synthetic condition, low in price of raw materialsand easy in commercial development. The prepared basophilia mimic enzyme has good peroxidase activity under the extreme alkaline pH condition; and moreover, the dispersity in water is good, and the application prospect in the field such as pollutant treatment, detection under the extreme alkaline condition and the like is good.